DOES KNOWLEDGE OF MEDICATION PRICES PREDICT PHYSICIANS’ SUPPORT FOR COST EFFECTIVE PRESCRIBING POLICIES?
Main Article Content
Keywords
Reference drug pricing, generic substitution, drug costs, British Columbia, survey
Abstract
Background
British Columbia implemented a generic substitution (GS) and Reference Drug Program (RDP) to contain drug expenditures without negatively affecting health outcomes. Years after implementation, these policies remain controversial among physicians.
Objective
To assess British Columbia general practitioners’ (GPs) opinions of RDP and GS stratified by knowledge of drug costs.
Methods
In telephone interviews, GPs ranked the economic and clinical appropriateness of drug policy options on a 5-point Likert scale. Responses to economic questions were stratified and compared according to the accuracy (+ $10 of the actual cost) of GPs’ cost estimates for a 30-day supply of atorvastatin and omeprazole.
Results
The majority of 210 interviewed GPs rated the economic appropriateness of GS and RDP positively (79% and 65%) but fewer rated them clinically appropriate (60% and 43%). Ratings for GS were more favorable than RDP, economically (mean=4.3 vs. 3.8, p=0.0005) and clinically (mean=3.7 vs. 3.1, p=0.006). GP’s assessment of the therapeutic equivalence among ACE inhibitors and among CCBs correlated with their ratings of the respective RDPs (?=0.3, p=0.03, and ?=0.4, p=0.02). GPs underestimated the price for omeprazole by C$28 (33%) and atorvastatin by C$28 (34%). GPs with accurate cost estimates were equally as likely to favorably rank the economic appropriateness of RDP as those with inaccurate estimates (mean = 3.7 vs. 4.0, p=0.0847). GS was assessed similarly (mean = 4.2 vs. 4.5, p=0.0712).
Conclusions
In British Columbia, the majority of GPs hold favorable opinions of GS and RDP; but, simply educating physicians about drug prices will not make them more supportive of cost-containment policies.
References
2. Executive Committee on Therapeutic Agents. MEMORANDUM NO. 10-94-003. Washington DC: Veterans Health Administration; 1994.
3. Banahan BF, 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications.[see comment]. Arch Intern Med 1997;157(18):2080-2088.
4. National Institute for Health Care Management. A primer: generic drugs, patents, and the pharmaceutical marketplace. Available at: http://www.nihcm.org/finalweb/GenericsPrimer .pdf. Accessed April 14, 2006.
5. Gleiter CH, Gundert-Remy U. Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 1994;11(1):1-6.
6. Anonymous. Final Task Force Report on Bioavailability and Bioequivalence of Psychotropic Drugs. Psychopharmacol Bulletin 1980;16(3):9-13.
7. Glickman L, Bruce EA, Caro FG, Avorn J. Physicians' knowledge of drug costs for the elderly. J Am Ger Soc 1994;42(9):992-996.
8. American Medical Association. Generic drugs (A-02). Available at: http://www.ama- assn.org/ama/pub/category/print/15279.html. Accessed April 14, 2006.
9. Consumer reports best buy drugs. Frequently Asked Questions. Available at: http://www.crbestbuydrugs.com/aboutus_faqs.h tml#14. Accessed April 14, 2006.
10. Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005;43(10):472- 479.
11. Schneeweiss S, Maclure M, Dormuth C, Avorn J. Pharmaceutical cost containment with reference-based pricing: time for refinements. CMAJ 2002;167(11):1250 -1251.
12. Huskamp HA, Rosenthal MB, Frank RG, Newhouse JP. The Medicare prescription drug benefit: how will the game be played? Health Aff 2000;19(2):8-23.
13. Schneeweiss S. Effectiveness of reference drug programs and policy implications. Health Pol 2007;81:17-28.
14. Ministry of Health. New prescription drug policy to save money and protect Pharmacare. British Columbia: Ministry of Health and Ministry Responsible for Seniors; 1995.
15. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference- based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ 2001;165(8):1011-1019.
16. Pharmacare. What is the Reference Drug Program (RDP)? Available at: http://www.hlth.gov.bc.ca/pharme/rdp/answer2 8.html. Accessed May 5, 2006.
17. Woollard RF. Opportunity lost: a frontline view of reference-based pricing. CMAJ 1996;154:1185-1188.
18. Anis A. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia. CMAJ 2002;166:763-764.
19. Boulet AP, Tessier G. Reference-based pricing in British Columbia: implications for cardiologists--an analysis. Can J Cardiol 1997;13:46-51.
20. Kent H. BC's reference-based pricing stirs controversy. CMAJ 2000;162(8):1190.
21. Bourgault C, Elstein E, Le Lorier J, Suissa S. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin- converting-enzyme inhibitors. CMAJ 1999;161:255-260.
22. Mullens A. Reference -based pricing: will other provinces follow the BC lead? CMAJ 1998;158:239-241.
23. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002;166:1655 -1662.
24. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference- based pricing for angiotensin- converting enzyme inhibitors on drug utilization.[see comment]. CMAJ 2002;166:737-745.
25. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin- converting-enzyme inhibitors. N Engl J Med 2002;346:822-829.
26. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003;74:388 -400.
27. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin- converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004;42:653 -660.
28. British Columbia Ministry of Health. Report of the Reference Drug Program Consultation Panel. Available at: http://www.hlth.gov.bc.ca/cpa/publications/rdp panel.pdf. Accessed May 5, 2006.
29. Narine L, Senathirajah M, Smith T. Evaluating reference-based pricing: initial findings and prospects. CMAJ 1999;161:286-288.
30. Hoffman J, Barefield FA, Ramamurthy S. A survey of physician knowledge of drug costs. J Pain Symptom Manage 1995;10:432-435.
31. Oppenheim GL, Erickson SH, Ashworth C. The family physician's knowledge of the cost of prescribed drugs. J Fam Pract 1981;12:1027-1030.
32. Weber ML, Auger C, Cleroux R. Knowledge of medical students, pediatric residents, and pediatricians about the cost of some medications. Pediatr Pharmacol 1986;5:281 -285.
33. Miller LG, Blum A. Physician awareness of prescription drug costs: a missing element of drug advertising and promotion. J Fam Pract 1993;36:33-36.
34. Fowkes FG. Doctors' knowledge of the costs of medical care. Med Educ 1985;19(2):113-117.
35. Beringer GB, Biel M, Ziegler DK. Neurologists' knowledge of medication costs. Neurology 1984;34:121-122.
36. Ryan M, Yule B, Bond C, Taylor RJ. Scottish general practitioners' attitudes and knowledge in respect of prescribing costs.BMJ 1990;300:1316-1318.
37. Walzak D, Swindells S, Bhardwaj A. Primary care physicians and the cost of drugs: a study of prescribing practices based on recognition and information sources. J Clin Pharmacol 1994;34:1159-1163.
38. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000;160:2799-2803.
39. Korn LM, Reichert S, Simon T, Halm EA. Improving physicians' knowledge of the costs of common medications and willingness to consider costs when prescribing. J Gen Intern Med 2003;18:31 -37.
40. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PloS Med 2007;4:e283.
41. Therapeutics Initiative. The Therapeutics Initiative. Available at: www.ti.ubc.ca. Accessed June 12, 2006.
42. EQIP. EQIP: Education for Quality Improvement with Physicians. Available at: www.eqip.ca. Accessed June 12, 2006.
43. Indepen dent Drug Information Service. Independent Drug Information Service: Balanced data about medications. Available at: www.rxfacts.org. Accessed June 12, 2006.
44. British Columbia Medical Association. Policy Backgrounder: Electronic Transfer of Patient Records. March 2003. Available at: http://www.bcma.org/public/news_publications /publications/policy_backgrounders/Electronic Transfer.asp . Accessed January 7, 2008.
45. Government Health IT. British Columbia e- health gets $134M. May 2, 2006. Available at: http://www.govhealthit.com/online/news/94246
-1.html . Accessed January 7, 2008.
46. British Columbia Ministry of Health. E-health and PharmaNet: Building Electronic Health Records for B.C. Residents. March 2007. Available at: http://www.healthservices.gov.bc.ca/pharme/ne wsletter/edrugupdate2.pdf. Accessed January 7,2008.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.